Home > Neurology > ECTRIMS 2019 > Optimising Long-Term Benefit of MS Treatment > Treatment escalation over induction therapy

Treatment escalation over induction therapy

Presented By
Dr Emmanuelle Waubant, University of California, San Francisco, USA
Conference
ECTRIMS 2019
Dr Emmanuelle Waubant (University of California, San Francisco, CA, USA) discussed why treatment escalation is the preferred principle over induction therapy. With respect to long-term outcomes in MS, there is a lot of heterogeneity. Patients can have different clinical and anatomical relapse locations, as well as different relapse frequency, severity, and recovery. Up to 20% of patients have “benign” disease, defined as having an EDSS ≥2.0 after 10-year duration. Although untreated MS may shorten life span by 6 years on average, many patients on moderately effective disease-modifying treatments (DMTs) have good outcomes in the long term. For example, it was shown that 69.8% of patients with clinically isolated syndrome on IFN-beta had EDSS <3.0 by year 11 [1]. Several clinical and MRI characteristics at onset predict poor outcome in cohorts, but not always in individual patients. Very little is known about the long-term safety and efficacy of or...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on